🚨 NeOnc completes enrollment in its pivotal NEO100 Phase 2a trial for IDH1-mutant recurrent glioma. Preliminary data coming Q2 2026. This milestone follows positive results from a 24-patient cohort shared on the Nov. 12 investor call. investors.neonc.com/news-rel… #NTHI #NEO100 #Biotech #Glioma #CNS